Abstract | BACKGROUND: OBJECTIVES: PATIENTS AND METHODS: Tissue microarrays from formalin-fixed paraffin-embedded resection material of 247 female and 164 male breast cancer patients were stained for PD-1 and PD-L1 by immunohistochemistry. RESULTS: PD-1 expression on tumor-infiltrating lymphocytes was significantly less frequent in male than in female cancers (48.9 vs. 65.3%, p = 0.002). In contrast, PD-L1 expression on tumor and immune cells did not differ between the two groups. In male breast cancer, PD-1 and tumor PD-L1 were associated with grade 3 tumors. In female breast cancer, PD-1 and PD-L1 were associated with comparably worse clinicopathological variables. In a survival analysis, no prognostic value was observed for PD-1 and PD-L1 in either male and female breast cancer. In a subgroup analysis, female patients with grade 3/ tumor PD-L1-negative or ER-negative/immune PD-L1-negative tumors had worse overall survival. CONCLUSIONS:
|
Authors | Quirine F Manson, Natalie D Ter Hoeve, Horst Buerger, Cathy B Moelans, Paul J van Diest |
Journal | Targeted oncology
(Target Oncol)
Vol. 13
Issue 6
Pg. 769-777
(12 2018)
ISSN: 1776-260X [Electronic] France |
PMID | 30519815
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- B7-H1 Antigen
- Biomarkers, Tumor
- CD274 protein, human
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- B7-H1 Antigen
(biosynthesis, immunology)
- Biomarkers, Tumor
(biosynthesis, immunology)
- Breast Neoplasms
(immunology, pathology)
- Breast Neoplasms, Male
(immunology, pathology)
- Female
- Humans
- Male
- Middle Aged
- Prognosis
- Programmed Cell Death 1 Receptor
(biosynthesis, immunology)
- Retrospective Studies
- Sex Factors
|